{"as_of":"2026-08-15T03:42:00Z","caps":{"database_statements":6,"inbound":100,"outbound":100},"context_digest":"sha256:ecd7b6ff6b709c0f5b2098d6796f129dc2e9d195e715b78795be1b3bdfb6fb85","coverage":[{"denominator":46,"lane":"reference_resolution","note":"Typed states for the displayed outbound observations.","records_observed":46,"source":"paper_references, paper_reference_links","source_observed_at":"2026-08-05T05:49:19.775002Z","state":"measured"},{"denominator":46,"lane":"standing_notices","note":"One-hop event checks from named stored sources.","records_observed":46,"source":"scholarly_work_events, retraction_status_cache","source_observed_at":"2026-08-14T06:32:32.682623+00:00","state":"measured"},{"denominator":0,"lane":"inbound_itemization","note":"Pith citing papers itemized under the disclosed page cap.","records_observed":0,"source":"paper_references, paper_reference_links","source_observed_at":null,"state":"measured"},{"denominator":1,"lane":"external_citation_measurements","note":"A source-named dated measurement, never combined with another source.","records_observed":0,"source":"cited_works","source_observed_at":null,"state":"measured"}],"external_citation_measurements":[],"inbound":[],"links":{"evidence":"/evidence","html":"/paper/2509.04939/citation-record","integrity":"/paper/2509.04939/integrity","json":"/paper/2509.04939/citation-record.json","paper":"/paper/2509.04939"},"outbound":[{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/s41573-018-0006-z","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Delivery technologies for cancer immunotherapy","venue":"Nature Reviews Drug Discovery","work_id":"e53be739-3c93-4432-947d-8f260ca32762","year":2019},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":1,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.532310Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:e72e682f9a9c8c84081dfe91ea0b83a1b17336631300da2e0c11fc2d58d3f5a2","observation_id":"2d1f01e1-b7ad-45b1-8479-b0353d0626e6","resolution":{"observed_at":"2026-08-05T05:49:20.455166Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:19.538468Z","title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","venue":null,"work_id":null,"year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":2,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.538468Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:ad521abfabab4b6cf304a23ae0088b3b65f14d0cf9bf74977fc418773a0b7e22","observation_id":"298dc4a0-5ec2-4821-9d73-aaebddb15780","resolution":{"observed_at":"2026-08-05T05:49:19.538468Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(17)30074-8","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","venue":"地学教育と科学運動","work_id":"165580cd-af91-4e64-8c32-98ca72bd9826","year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":3,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.545999Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:68f3b3abbbbfa5ec597e94ce55611b9d9a30cb04afe144469ba628a9cd329fbb","observation_id":"b398435c-4555-46e2-ad74-817fb94e8253","resolution":{"observed_at":"2026-08-05T05:49:20.427235Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-05T06:18:32.70995+00:00","source":"paper_reference_links","state":"open"},"event_date":"2019-04-30","event_type":"correction","notice_doi":"10.1016/s1470-2045(19)30240-2","provenance":{"observed_at":"2026-07-11T03:12:31.049135+00:00","source":"crossref","source_record_id":"10.1016/s1470-2045(19)30240-2->10.1016/s1470-2045(17)30074-8:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1136/jitc-2024-010311","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","venue":"Journal for ImmunoTherapy of Cancer","work_id":"538acc7e-0faa-4e6f-8b70-6bcf1f32c37d","year":2025},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":4,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.552269Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:89eef75cd1db203022134cc7357f2b37d59d72a2af365a4cf4bd5c8acfc1898b","observation_id":"7ddadf5b-0157-4241-b803-7e0aab8a8b00","resolution":{"observed_at":"2026-08-05T05:49:20.411151Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-05T06:18:25.580924+00:00","source":"paper_reference_links","state":"open"},"event_date":"2025-03-03","event_type":"correction","notice_doi":"10.1136/jitc-2024-010311corr1","provenance":{"observed_at":"2026-07-11T03:07:12.739551+00:00","source":"crossref","source_record_id":"10.1136/jitc-2024-010311corr1->10.1136/jitc-2024-010311:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/s41598-024-80301-9","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Why PD -L1 expression varies between studies of lung cancer: results from a Bayesian meta -analysis","venue":"Scientific Reports","work_id":"079df839-240f-43d9-84ed-7d241e430715","year":2025},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":5,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.557450Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:b67b5b673a605457b73a89745e9d231b03fdf1a1e19ce2b8ce48f2689a9d8f5e","observation_id":"43ab2120-b569-4f54-ac7d-ac3e1eaf8e91","resolution":{"observed_at":"2026-08-05T05:49:20.394913Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/s41571-020-0392-0","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal –Anal Task Forces whitepaper","venue":"Nature Reviews Clinical Oncology","work_id":"11ce2d05-5f06-4abf-b425-ddecfb204b52","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":6,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.563384Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:77241d00a8fc6b7e1ddcf24d4df6e222865b46ebc49c9cb9640594ab4d728061","observation_id":"3d5ea0ee-b24f-419e-806b-220503a42557","resolution":{"observed_at":"2026-08-05T05:49:20.378782Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/s41467-018-07466-6","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Comprehensive human cell -type methylation atlas reveals origins of circulating cell -free DNA in health and disease","venue":"Nature Communications","work_id":"12698399-0274-4f0a-8523-aaeb6bdef5f7","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":7,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.569703Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:ba6cf8ae6f61527626ece87773c1feb10271be4c792b7c236d4f891386a84a07","observation_id":"57b7cd80-c061-4047-9026-61e325d9996a","resolution":{"observed_at":"2026-08-05T05:49:20.361809Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1158/2159-8290.cd-21-1252","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer","venue":"Cancer Discovery","work_id":"9b33ad29-7037-4972-bd9a-d7c00fef8b50","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":8,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.575392Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:b5d2c41164fc527647a62753664d7f9e604be9703e6ca90a0c808ee26be997dd","observation_id":"99085dbd-aa6d-428e-9967-ac29bdfa2ba7","resolution":{"observed_at":"2026-08-05T05:49:20.344801Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.molmed.2020.01.012","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":"Cell -Free DNA and Apoptosis: How Dead Cells Inform About the Living","venue":"Trends in Molecular Medicine","work_id":"de3e41cc-396e-4303-a953-3f97ed339f94","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":9,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.580893Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:fa69c4291bb2292b16bb7db8c7764017ab26446a4dff29d95a09f4d4874274c6","observation_id":"7fec7e57-bd33-4380-8186-5e84274e6a0b","resolution":{"observed_at":"2026-08-05T05:49:20.326279Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":"2020.10316","doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.787719Z","title":"The main sources of circulating cell -free DNA: Apoptosis, necrosis and active secretion","venue":null,"work_id":"1e4d5eee-2b38-494c-a2c4-d52f29d12d49","year":2021},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":10,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.586745Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:170808919e5512f631ae748e8dd6f8754206f00fe5202e26b721ae75aebc1f6b","observation_id":"405ba787-3285-4df4-a799-d00f3d92d6cf","resolution":{"observed_at":"2026-08-05T05:49:20.796278Z","resolver_source":"raw_fallback","status":"metadata_mismatch"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/cr.2014.44","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Double -stranded DNA in exosomes: a novel biomarker in cancer detection","venue":"Cell Research","work_id":"254010b5-c28e-49d6-a93d-66015de53ad0","year":2014},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":11,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.591852Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:5756423891f30a47af8e5c3dcbf7e7cf08bd3428f02a8930fc7cff829801ae4f","observation_id":"96a69e91-a23c-4d82-b469-17e113bd6381","resolution":{"observed_at":"2026-08-05T05:49:20.310507Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.4155/fsoa","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.288025Z","title":"Kinetics of circulating cell -free DNA for biomedical applications: critical appraisal of the literature","venue":null,"work_id":"f5e7f43f-f2bb-491d-8b27-b0d29a20d43d","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":12,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.597163Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:afbff29c8a21e07a50d02e4b232dad8280c6bb059f68fd67c662cdf48e5f51af","observation_id":"43db0ccf-9f51-4925-8dbf-516ddf89a5a9","resolution":{"observed_at":"2026-08-05T05:49:20.294256Z","resolver_source":"doi_truncated","status":"malformed_identifier"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.ctrv.2013.10.003","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":"Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities","venue":"Cancer Treatment Reviews","work_id":"e53dc2c8-e223-4137-a40c-3f33c20f38ce","year":2014},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":13,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.603198Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:80740b1f3f1ef84aefc03fc91f5c40b0e86081ccaa06dc8f65bab239253e17ae","observation_id":"810bd917-29e8-446c-8201-7b8d128bb2c1","resolution":{"observed_at":"2026-08-05T05:49:20.277300Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1007/s10555-016-9629-x","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:12:12.796739Z","title":"Origins, structures, and functions of circulating DNA in oncology","venue":"Cancer and Metastasis Reviews","work_id":"44b47c2b-8a81-4933-8c52-a82d4b870cd4","year":2016},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":14,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.608239Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:e9a32e7548713c37f7555d41e4eef08c39c83407427c6eb329a53506891d614e","observation_id":"4fc7de63-3242-46b4-9c5d-9837be5bf5f2","resolution":{"observed_at":"2026-08-05T05:49:20.260967Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:19.613440Z","title":"Current and Future Clinical Applications of ctDNA in Immuno -Oncology","venue":null,"work_id":null,"year":2022},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":15,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.613440Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:053c00a3289886ab9fe65c725446237682168a892189ec7bc29061781e300cb1","observation_id":"a608f72f-e9db-40fa-9faa-4707182b4edf","resolution":{"observed_at":"2026-08-05T05:49:19.613440Z","resolver_source":null,"status":"malformed_identifier"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1186/1471-2164-16-s13-s1","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Non -random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation","venue":"BMC Genomics","work_id":"6d761f33-b114-4283-b4fe-78a073ff70ba","year":2015},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":16,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.618343Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:4ef5d4d1672a359c54b25093d6c388cb626f185e8594d6bf50193a5936e2bca2","observation_id":"9787e6e3-3bfc-4c5b-9c70-286609e83d0e","resolution":{"observed_at":"2026-08-05T05:49:20.233844Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1126/scitranslmed.aat4921","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Enhanced detection of circulating tumor DNA by fragment size analysis","venue":"Science Translational Medicine","work_id":"5705806b-a007-445f-917c-ff349339eef1","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":17,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.623643Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:6cdb59e15b4fad7befec47ad783af984bd3d0ebcd200ffefb80cc435418826f4","observation_id":"f61a4903-ab85-456d-bafd-b8ebaf409ddb","resolution":{"observed_at":"2026-08-05T05:49:20.217951Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.3390/ijms24021503","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Cell-Free DNA Fragmentomics: The Novel Promising Biomarker","venue":"International Journal of Molecular Sciences","work_id":"41dddd3d-7ae5-4f53-b405-670241951f4f","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":18,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.629387Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:effa99f58c11ad1a15fa8e0e79b68ddb9f3d94f59e2673d2f420438a339d2e3d","observation_id":"2ad8611f-f857-4c84-8c87-b46e281b7504","resolution":{"observed_at":"2026-08-05T05:49:20.201121Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1021/acs.analchem.7b04034","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High -Sensitivity Characterization of Circulating Cell -Free DNA","venue":"Analytical Chemistry","work_id":"7936f81a-f0b4-4d75-b2c6-670cd411769b","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":19,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.634632Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:73dc6e9883de593eee424d5bdd46becd4d876adddfb3d21088d8db1025a97f84","observation_id":"042078d5-c396-4ca6-9402-4a236f2fe688","resolution":{"observed_at":"2026-08-05T05:49:20.184377Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1021/acs.analchem.3c00998","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Size and Concentration of Cell -Free DNA Measured Directly from Blood Plasma, without Prior DNA Extraction","venue":"Analytical Chemistry","work_id":"d85e285f-4dbf-469a-b389-370cfc3d1597","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":20,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.639276Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:ab4540487e92df45bd5726c827d3a39713ab98d0f65860710b83ebabcc40073e","observation_id":"424bb5ba-c91d-4aaa-ae02-e424dc4e2fa8","resolution":{"observed_at":"2026-08-05T05:49:20.166246Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.lungcan.2017.01.013","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":"Pretreatment neutrophil -to-lymphocyte ratio as a marker of outcomes in nivolumab -treated patients with advanced non -small-cell lung cancer","venue":"Lung Cancer","work_id":"d8c057c1-699e-49e0-b3a3-f282ad14d06a","year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":21,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.644663Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:7513ae5a50283ae9825ea34a24e83b956b25db42b722649c1ce33f60eedce480","observation_id":"6d59985a-efbb-406e-a4e1-2abe895dc0c6","resolution":{"observed_at":"2026-08-05T05:49:20.150706Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":"2017.4771","doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.699282Z","title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non –Small Cell Lung Cancer","venue":null,"work_id":"c0262d7a-dfe2-4a7a-8068-47989ae8ea3a","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":22,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.649697Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:bb7dad3bf67e3d6428be6d20b8a639bd0e77aba9cc04c61b9fd395be2ed24fff","observation_id":"da0d5039-df40-41cb-92c8-34af7c76d66e","resolution":{"observed_at":"2026-08-05T05:49:20.707489Z","resolver_source":"raw_fallback","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1801005","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Pembrolizumab plus Chemotherapy in Metastatic Non –Small-Cell Lung Cancer","venue":"New England Journal of Medicine","work_id":"2c4b8df9-7496-4d57-b446-13f3b409a722","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":23,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.654543Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:c3f3262182fff4758ace7cb2351a0618d4364d2e71c69206f076f73d61103d1e","observation_id":"50a57073-5b69-4dac-a816-5ea09aabf093","resolution":{"observed_at":"2026-08-05T05:49:20.135790Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s1470-2045(17)30421-7","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":null,"venue":"The Lancet Oncology","work_id":"a82fd325-212b-4d86-892d-01e98666e090","year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":24,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.659548Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:f641310c25884c120429f0bf7918dd78cddfe113bebe9b3171bae137f01c90ce","observation_id":"0cd4bc2e-0d4d-4a2b-ae3c-13a7c9313357","resolution":{"observed_at":"2026-08-05T05:49:20.119404Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/s0140-6736(19)32591-7","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":null,"venue":"The Lancet","work_id":"b2594f04-2b95-4540-97f4-6fb9e1bf2cf8","year":2019},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":25,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.665125Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:97d92a1f3c6efd2bc42fd931e28313c23bdab12048e594c8e9568787b6f4b319","observation_id":"06ad2ec5-99ac-4c14-94c1-85c25cacdb03","resolution":{"observed_at":"2026-08-05T05:49:20.103130Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[{"edge_observation":{"observed_at":"2026-08-05T06:18:37.366034+00:00","source":"paper_reference_links","state":"open"},"event_date":"2020-01-23","event_type":"correction","notice_doi":"10.1016/s0140-6736(20)30116-1","provenance":{"observed_at":"2026-07-11T03:17:24.633565+00:00","source":"crossref","source_record_id":"10.1016/s0140-6736(20)30116-1->10.1016/s0140-6736(19)32591-7:correction"}},{"edge_observation":{"observed_at":"2026-08-05T06:18:34.440174+00:00","source":"paper_reference_links","state":"open"},"event_date":"2020-02-21","event_type":"correction","notice_doi":"10.1016/s0140-6736(20)30254-3","provenance":{"observed_at":"2026-07-11T03:14:21.540322+00:00","source":"crossref","source_record_id":"10.1016/s0140-6736(20)30254-3->10.1016/s0140-6736(19)32591-7:correction"}},{"edge_observation":{"observed_at":"2026-08-05T06:18:38.113482+00:00","source":"paper_reference_links","state":"open"},"event_date":"2021-06-10","event_type":"correction","notice_doi":"10.1016/s0140-6736(21)01119-3","provenance":{"observed_at":"2026-07-11T03:17:39.319921+00:00","source":"crossref","source_record_id":"10.1016/s0140-6736(21)01119-3->10.1016/s0140-6736(19)32591-7:correction"}}],"reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1056/nejmoa1606774","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Pembrolizumab versus Chemotherapy for PD -L1–Positive Non –Small-Cell Lung Cancer","venue":"New England Journal of Medicine","work_id":"edcbee05-f012-4bfe-b0de-ec013d829203","year":2016},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":26,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.671836Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:ebda851704592a47654488e3cbaf0f3fcf73ed54d3d0ed062372e439b94cb4d2","observation_id":"1429c87c-c255-4b6d-b1d9-1b290a9cbd10","resolution":{"observed_at":"2026-08-05T05:49:20.086543Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":null,"pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:19.676948Z","title":"Comparison of Biomarker Modalities for Predicting Response to PD -1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta -analysis","venue":null,"work_id":null,"year":2019},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":27,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.676948Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:cec43164c7e30a445ed575ef7bcfadc8daad89cd544f68736d6878a9a1054e70","observation_id":"b668548a-eca3-42d8-9fce-8e486e7cce47","resolution":{"observed_at":"2026-08-05T05:49:19.676948Z","resolver_source":null,"status":"unresolved"},"standing_notice":{"events":[],"reason":"canonical_work_link_unavailable","source_receipts":[],"state":"unavailable"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.lungcan.2017.07.024","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet- to-Lymphocyte ratio (PLR) as prognostic markers in patients with non -small cell lung cancer 37 (NSCLC) treated with nivolumab","venue":"Lung Cancer","work_id":"c8cb053b-2daf-4ee0-806d-11e77341d590","year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":28,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.681768Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:69af38444c6804ece3c3efea13968ced9cc273a0389b23f04e6319ed9db344a3","observation_id":"d9dc194a-edad-4e50-b701-e2156a838660","resolution":{"observed_at":"2026-08-05T05:49:20.068620Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.3390/biom13121803","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Neutrophil -to- Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond","venue":"Biomolecules","work_id":"0f702d2c-62bc-4ce0-9ef5-0ee23c79b7f2","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":29,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.687224Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:1595797955296f6b066a591a09ce8fa3ab961e82516520d3224f1d05bb6447da","observation_id":"0475d6a1-094b-4f77-831e-a989989e4a48","resolution":{"observed_at":"2026-08-05T05:49:20.052297Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1186/s12967-018-1677-2","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer","venue":"Journal of Translational Medicine","work_id":"f61e71f2-5970-4624-9e7a-9ad4ec697257","year":2018},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":30,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.692091Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:d1cf45afa350730cd4357da6246ddb4ffb0cb66679f1fece5d2abcdcbf8f2ef2","observation_id":"032a792b-57db-4756-bd9a-239305222cb6","resolution":{"observed_at":"2026-08-05T05:49:20.033532Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1038/s41591-023-02226-6","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non -small-cell lung cancer","venue":"Nature Medicine","work_id":"16b6b602-9304-4872-bed9-0c8cc4f780ce","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":31,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.697025Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:4aab70d31cff0879140d089149bea4c16ade6bf6e0a1ea36eed8ce6c0baca868","observation_id":"e73af332-0d43-4deb-9311-47fbd092d472","resolution":{"observed_at":"2026-08-05T05:49:20.015319Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1186/s12967-022-","metadata_source":"doi_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:19.993067Z","title":"The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs","venue":null,"work_id":"758a1fe8-6de8-4017-ae7d-7d67fa834215","year":2022},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":32,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.702987Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:5d1075b494e3868e382db7cec4f0d3cd25e37a683561ee44a07b0d158d4352b2","observation_id":"ffb75787-2454-41cf-9bdc-38f36d430a6a","resolution":{"observed_at":"2026-08-05T05:49:19.998737Z","resolver_source":"doi_truncated","status":"malformed_identifier"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1073/pnas.1500076112","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients","venue":"Proceedings of the National Academy of Sciences","work_id":"9b2121c0-c197-424f-a349-fcf3d90e7995","year":2015},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":33,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.707930Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:f79168c1adb6a94372c0b2115aae64e140ee1065bde606632d56b964f62a9ce8","observation_id":"098dd73f-7f04-42f1-9a08-f6fa36c68bfe","resolution":{"observed_at":"2026-08-05T05:49:19.982459Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1016/j.cell.2015.11.050","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T06:46:29.746714Z","title":"Cell -free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues -Of-Origin","venue":"Cell","work_id":"a688ad02-1356-47f3-9d51-67ab0ffacbbd","year":2016},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":34,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.712637Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:a01f8204b6a5dce05c5f7a757aaa2eb4b838940499ec2e8010135282608c3362","observation_id":"f05924b7-599e-4319-9ec0-a78eb942f7ef","resolution":{"observed_at":"2026-08-05T05:49:19.966006Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1126/scitranslmed.3001720","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus","venue":"Science Translational Medicine","work_id":"a6292a46-baf8-4390-b4b6-23fa74cb819a","year":2010},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":35,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.717149Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:8c750906a237aba6647afb0c9e33d6126a170b6073f9e1152b94ade811f7d401","observation_id":"edab2a52-acb1-4bdf-825d-ee8d352a2702","resolution":{"observed_at":"2026-08-05T05:49:19.948567Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.826020Z","title":"DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells1","venue":null,"work_id":"3b36c18f-3159-4af4-ae4a-1a7f6b2bd752","year":2001},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":36,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.722739Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:20356888c03451e0ce6ac31cd5dbe6511ec552eb185c143e57b6a3921d8f5a04","observation_id":"20956a65-0aa3-424d-b2c2-7a1f9628bab8","resolution":{"observed_at":"2026-08-05T05:49:20.831643Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.807130Z","title":"Increased plasma DNA integrity in cancer patients","venue":null,"work_id":"35448cfe-066a-44b4-a823-21fc96f30483","year":2003},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":37,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.727742Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:b3a7c9b10f58309b2a989906ddad5eec8014539b3aac82acd9e4f446f66dbee2","observation_id":"4951f630-e9a4-444f-b1ed-ba012ae0eca8","resolution":{"observed_at":"2026-08-05T05:49:20.814248Z","resolver_source":"raw_fallback","status":"verified_fuzzy"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1158/2159-8290.cd-23-0824","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"A New Paradigm of the Origins of Circulating DNA in Patients with Cancer","venue":"Cancer Discovery","work_id":"d7dfc50b-c2c3-47fe-bd4f-adb46f22e885","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":38,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.734526Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:4902efb72196c4c80bf1af3b0853c1a7674ddd1bb427381ce0a9500e924482e8","observation_id":"44aed982-cc2f-4075-a69c-7161b9b9cfa7","resolution":{"observed_at":"2026-08-05T05:49:19.930896Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.3390/pharmaceutics12080758","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Like a Rolling Stone: Sting-Cgas Pathway and Cell -Free DNA as Biomarkers for Combinatorial Immunotherapy","venue":"Pharmaceutics","work_id":"82a9abbd-c892-4d02-b51f-83efd1a2698a","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":39,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.739894Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:affd824a1c7e59d29683855e8be30429dc71473de78bad069cd32d63a6dbc260","observation_id":"571ca28f-9c9b-4f1b-9786-20d16f1f3dba","resolution":{"observed_at":"2026-08-05T05:49:19.915460Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.3390/ijms21218062","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Putative Origins of Cell -Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms","venue":"International Journal of Molecular Sciences","work_id":"9f8c2ac2-a1f0-4519-879b-6e8ecea84032","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":40,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.745113Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:9ebf8da17eaf2f69437895dfe21a23e5b787d74706b0c52f858af6dfe7eecbaf","observation_id":"8955c197-eada-478b-bac0-5d53194aae26","resolution":{"observed_at":"2026-08-05T05:49:19.897519Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1126/science.aaw3616","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","venue":"Science","work_id":"b0503675-41eb-4f7a-ac3f-322865fcf339","year":2021},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":41,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.750141Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:b3051aa26c115e60981d2d2907008417d03679740dc5ed7e94e151083a171318","observation_id":"b117446b-6653-41e7-b044-6d231d6e9c69","resolution":{"observed_at":"2026-08-05T05:49:19.880118Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1158/2159-8290.cd-19-0761","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"The cytosolic DNA -sensing cGAS-STING pathway in cancer","venue":"Cancer Discovery","work_id":"b71bb26b-a5f9-408b-a649-1a87fa78582c","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":42,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.755173Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:5b34f6e0de1f8561773a314dc51fcdee0580b3b9047fd61c265ae99e9b0cf432","observation_id":"3761d2a5-c296-4d61-8c4a-1d107175591f","resolution":{"observed_at":"2026-08-05T05:49:19.864211Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.15252/embr.201744017","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"cGAS is activated by DNA in a length‐ dependent manner","venue":"EMBO Reports","work_id":"0fc4a0dd-4a7b-46fc-b456-94378c400ca9","year":2017},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":43,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.760014Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:0424c6331602d4fe842e0c6b8063f2faa16612ef1e2911c56e4632ea1046d286","observation_id":"c19d24b5-82e5-42a9-ab4b-1ad2f15a72ed","resolution":{"observed_at":"2026-08-05T05:49:19.847526Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":"2023.10107","doi":null,"metadata_source":"raw_reference","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-05T05:49:20.535454Z","title":"Elevated cfDNA after exercise is derived primarily from mature polymorphonuclear neutrophils, with a minor contribution of cardiomyocytes","venue":null,"work_id":"0c30533e-2d65-4ba2-8ce2-d7e47fe76c5a","year":2023},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":44,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.765614Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:7c72ae20cc7e901e2e0873fc76b4639cb6f5249641ce024f99841e9ba626cb9c","observation_id":"40311d99-7fee-4e7f-ab5b-7a0d7c79a2f7","resolution":{"observed_at":"2026-08-05T05:49:20.543696Z","resolver_source":"raw_fallback","status":"metadata_mismatch"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1371/journal.pone.0023418","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"High Fragmentation Characterizes Tumour - Derived Circulating DNA","venue":"PLoS ONE","work_id":"424078cc-871b-493a-87d8-c41474d47d0d","year":2011},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":45,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.770099Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:42b8e5547455864725bb6a6458b8e588db881aca3195e359f880da658cfefb0b","observation_id":"fc5dfc78-1f32-4d7f-8b7a-3a1bd223819e","resolution":{"observed_at":"2026-08-05T05:49:19.831167Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}},{"citation":{"cited_paper":null,"cited_work":{"arxiv_id":null,"doi":"10.1002/cpt.1951","metadata_source":"openalex","pith_arxiv_id":null,"snapshot_observed_at":"2026-08-10T05:30:23.456663Z","title":"Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology","venue":"Clinical Pharmacology & Therapeutics","work_id":"5a803292-78a8-4a65-b958-94c5cd34c9e2","year":2020},"citing_paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","version":1},"reference_index":46,"source":"pdf_text","source_observed_at":"2026-08-05T05:49:19.775002Z"},"links":{"citing_paper":"/paper/2509.04939"},"observation_digest":"sha256:65444552a6d5a1c3187560ae254fb539458ff6efb671cbc54d79bb9f107f15ca","observation_id":"32160391-dd5a-4746-819c-1f18460c87fe","resolution":{"observed_at":"2026-08-05T05:49:19.814726Z","resolver_source":"doi","status":"verified_exact"},"standing_notice":{"events":[],"observation":"No event found in the named queried sources as of 2026-08-14T06:32:32.682623+00:00.","reason":null,"source_receipts":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"state":"measured"}}],"paper":{"arxiv_id":"2509.04939","last_updated":"2025-09-05T09:01:43Z","latest_version":1,"primary_category":"q-bio.QM","snapshot_observed_at":"2026-08-10T18:50:19.229050Z","submitted_at":"2025-09-05T09:01:43Z","title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors"},"reference_resolution":{"displayed":46,"state_counts":{"malformed_identifier":3,"metadata_mismatch":2,"parse_uncertain":0,"unresolved":2,"verified_exact":37,"verified_fuzzy":2},"total_outbound_references":46},"refusal":"A citation records a reference. It does not transfer a finding from one paper to another.","schema":"pith.paper-citation-record.v1","standing_sources":[{"observed_at":"2026-08-14T06:32:32.682623+00:00","source":"crossref"},{"observed_at":"2026-08-14T06:32:18.44784+00:00","source":"retraction_watch"}],"thesis":"As of 15 August 2026, this Paper Citation Record lists 46 of 46 outbound references and 0 inbound Pith citation observations for arXiv:2509.04939."}